Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Pipeline Review, H1 2016', provides in depth analysis on Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted pipeline therapeutics. 

The report provides comprehensive information on the Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)
- The report reviews Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) Overview 7
Therapeutics Development 8
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Products under Development by Stage of Development 8
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Products under Development by Therapy Area 9
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Products under Development by Indication 10
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Products under Development by Companies 14
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Products under Development by Universities/Institutes 17
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Therapeutics Assessment 19
Assessment by Monotherapy/Combination Products 19
Assessment by Mechanism of Action 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Companies Involved in Therapeutics Development 25
Calypso Biotech SA 25
Gilead Sciences, Inc. 26
Shulov Innovative Science Ltd. 27
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Drug Profiles 28
AQU-010 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
AQU-118 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
CALY-001 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
GS-5745 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Monoclonal Antibodies to Inhibit MMP-2 and MMP-9 for Immunology and Gastrointestinal Disorders - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ND-336 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
ND-478 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Dupuytren Contracture, Peyronies Disease and Transplantation - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Recombinant Protein to Target MMP-9 for Wounds - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
SI-1004 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
SI-1005 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecule to Inhibit Matrix Metalloproteinase 9 for Oncology - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecules to Inhibit MMP for Myocardial Infarction - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
ZEP-3 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Dormant Projects 45
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Discontinued Products 49
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Featured News & Press Releases 50
May 13, 2015: Abzena provides an update on the clinical development of one of the humanized antibodies created using its Composite Human Antibody technology 50
Dec 26, 2011: New Antibodies Treat Autoimmune Disease in Mice 50
Oct 08, 2011: Researchers from Notre Dame university create breakthrough in neurological diseases 51
Oct 06, 2011: Notre Dame researchers make neurological disease breakthrough 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54

List of Tables

Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Development by Companies, H1 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Assessment by Monotherapy/Combination Products, H1 2016 19
Number of Products by Stage and Mechanism of Action, H1 2016 20
Number of Products by Stage and Route of Administration, H1 2016 22
Number of Products by Stage and Molecule Type, H1 2016 24
Pipeline by Calypso Biotech SA, H1 2016 25
Pipeline by Gilead Sciences, Inc., H1 2016 26
Pipeline by Shulov Innovative Science Ltd., H1 2016 27
Dormant Projects, H1 2016 45
Dormant Projects (Contd..1), H1 2016 46
Dormant Projects (Contd..2), H1 2016 47
Dormant Projects (Contd..3), H1 2016 48
Discontinued Products, H1 2016 49